AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18784099
Drug: Surgical lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical lavage and arthroscopic debridement together with optimized physical and medical therapy
Trial: 22773282
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% glucose solution)
Trial: 8767241
Drug: Etomidate (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (in lipid emulsion) 0.25 mg/kg
Trial: 1443704
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg/kg
Trial: 1897306
Drug: Regularly or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regularly or irregularly administered toxoid doses
Trial: 6225405
Drug: Electroconvulsive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive treatment
Trial: 27321067
Drug: Client‐centred activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client‐centred activity of daily living intervention (CADL)
Trial: 22595038
Drug: donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil (5 mg q.d)
Trial: 17428104
Drug: Oral satraplatin
RxNorm normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral satraplatin plus prednisone
Trial: 8943507
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% (90 mg vaginal progesterone per day)
Trial: 8943507
Drug: Utrogestan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utrogestan (300 mg oral micronized progesterone)
Trial: 1647293
Drug: Naloxone (0.5-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.5-1.0 mg, i.m.) administered at 6, 30 and 54 h after methadone pre-treatment
Trial: 2072190
Drug: Oral triazolam
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral triazolam
Trial: 19863477
Drug: Albiglutide 15
RxNorm normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albiglutide 15 mg weekly
Trial: 19592625
Drug: Albiglutide 30
RxNorm normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 30 mg weekly
Trial: 12702897
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (500-2500 mg)
Trial: 27306347
Drug: Ciprofloxacin, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, amoxicillin, and omeprazole (CAO)
Trial: 17356388
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) > or =90 mg/L
Trial: 2659383
Drug: N-acetylcysteine (NAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), 200 mg x 3 daily for patients <30 kg or 400 mg x 2 daily for patients >30 kg
Trial: 19168019
Drug: Oral lyophilisate
RxNorm normalized name: ORAL LYOPHILISATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lyophilisate (Minirinmelt)
Trial: 19168019
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (lyophilisate and tablet)
Trial: 17360873
Drug: Tafenoquine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine (200 mg base/day for 3 days, followed by 200 mg/week for 8 weeks)
Trial: 28677349
Drug: HBB 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBB 20 mg
Trial: 7857751
Drug: ACE-inhibitor (enalapril)
RxNorm normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor (enalapril) added to conventional heart failure therapy
Trial: 11719353
Drug: G-PBSC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-PBSC
Trial: 17315706
Drug: Levitra (vardenafil;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levitra (vardenafil; 5 mg per os each other day)
Trial: 2764545
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 1,000 mg
Trial: 2764545
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 1,500 mg
Trial: 2764545
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 2,000 mg
Trial: 18768245
Drug: Magnesium (360mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (360mg daily)
Trial: 10665553
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (target international normalised ratio 3.0‐4.5, n=1339)
Trial: 10665553
Drug: Aspirin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (80 mg daily, n=1351)
Trial: 27115063
Drug: Fortified bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified bread (FP; 50 g bread fortified with 25 μg vitamin D3 plus placebo daily; n = 30)
Trial: 27115063
Drug: Supplement (SP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (SP; 50 g plain bread plus 25 μg vitamin D supplement daily; n = 30)
Trial: 27115063
Drug: Control (CP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CP; 50 g plain bread plus placebo daily; n = 30)
Trial: 24650128
Drug: High fibre
RxNorm normalized name: Adult high protein high fibre formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fibre supplement (HFS)
Trial: 15862926
Drug: Intravenous sodium-lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium-lactate infusion
Trial: 10337463
Drug: Anti-IFN alpha
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IFN alpha vaccine
Trial: 31523872
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs measured
Trial: 31523872
Drug: Baseline drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline drug use
Trial: 28245970
Drug: rAAV.sFlt‐1 subretinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV.sFlt‐1 subretinal injection (low-dose: 1 × 10^10 vector genomes; high-dose: 1 × 10^11 vector genomes)
Trial: 24714414
Drug: H.P. Acthar(®)
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H.P. Acthar(®) Gel (40 or 80 IU subcutaneously twice weekly)
Trial: 24714414
Drug: H.P. Acthar(®)
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H.P. Acthar(®) Gel
Trial: 17259872
Drug: HA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 1 at ages 6 and 12 months
Trial: 17259872
Drug: HA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 1 (6 and 12 months) vs group 3 (15 and 21 months)
Trial: 17259872
Drug: Routine vaccinations
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine vaccinations administered during infancy
Trial: 11449083
Drug: 28.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28.5 mg/day of isoflavones
Trial: 11449083
Drug: 57 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 57 mg/day of isoflavones
Trial: 11449083
Drug: 85.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 85.5 mg/day of isoflavones
Trial: 11449083
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of isoflavones
Trial: 2977262
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg Zoladex depot subcutaneous injection every 28 days for 12 weeks
Trial: 28989150
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg, 5 mL) during general anesthesia induction, post-operative day 1 and day 2
Trial: 28989150
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (5 mL) at corresponding time points
Trial: 27101674
Drug: Budensonide nasal
RxNorm normalized name: budesonide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budensonide nasal spray and desloratadine citrate disodium tablets for 4 weeks
Trial: 23563958
Drug: nab-paclitaxel 150
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 150 mg/m(2)
Trial: 23563958
Drug: nab-paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel 100 mg/m(2)
Trial: 16093415
Drug: Constraint‐induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced movement therapy (CIMT)
Trial: 20088415
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with Chinese herbal decoction plus western medicine (Group A)
Trial: 20088415
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine alone (Group D)
Trial: 11689273
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg per day
Trial: 24261771
Drug: Celecoxib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100 mg/dose, twice daily)
Trial: 24261771
Drug: Loxoprofen (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxoprofen (60 mg/dose, 3 times daily)
Trial: 21953376
Drug: gadobenate dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gadobenate dimeglumine (intravenous contrast agent)
Trial: 17155972
Drug: Apical periprostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apical periprostatic block with 5 mL of 1% lidocaine
Trial: 17155972
Drug: Basal periprostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal periprostatic block with 5 mL of 1% lidocaine
Trial: 10401901
Drug: Morphine patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine patient-controlled analgesia with ketorolac
Trial: 10401901
Drug: Morphine patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine patient-controlled analgesia without ketorolac (placebo)
Trial: 2365458
Drug: Leish vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leish vaccine 5 or Leish vaccine 6 with or without Corynebacterium parvum
Trial: 94089
Drug: No antithyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithyroid drugs before or when RAI was given
Trial: 28387919
Drug: CRT-D with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D with intensive drugs
Trial: 97779
Drug: Single morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single morning dose of Loperamide
Trial: 97779
Drug: Second bedtime
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second bedtime dose of Loperamide
Trial: 21440713
Drug: High-power pain
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-power pain threshold ultrasound (HPPTUS) therapy
Trial: 9648120
Drug: Caregiver information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver information about daily activities and performance ability
Trial: 1092725
Drug: Stelazine (STEL)
DrugBank: Trifluoperazine (DB00831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stelazine (STEL) 50 mg/day
Trial: 1092725
Drug: Loxapine (LOX)
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loxapine (LOX) 100 mg/day for four weeks
Trial: 15233676
Drug: Tegaserod 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 12 mg b.i.d.
Trial: 30268163
Drug: Oxygen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen plus conventional pain treatment
Trial: 30268163
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen mixture plus conventional pain treatment
Trial: 26753892
Drug: Imipramine 25
RxNorm normalized name: trimipramine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 25 mg once daily for 8 weeks
Trial: 12399193
Drug: 50 micro
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micro g MPL/AlPO(4)
Trial: 7655643
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide (OCT) administration (300 to 600 micrograms/day for 6 months)
Trial: 7655643
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide (OCT) administration
Trial: 1097194
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg indapamide daily
Trial: 1090415
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg frusemide daily
Trial: 28732289
Drug: Emotion-focused supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion-focused supportive therapy
Trial: 25641639
Drug: rhGH administration
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH administration (0.50 ± 0.06 mg/kg · wk) for 11.1 ± 4.8 months
Trial: 17720777
Drug: Miglustat 100
RxNorm normalized name: miglustat 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglustat 100 mg without food
Trial: 11704024
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with postoperative subconjunctival 5‐fluorouracil injections
Trial: 11704024
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with one-layer conjunctiva-Tenon capsule closure
Trial: 9059564
Drug: DHEA plus
RxNorm normalized name: Ascorbic Acid/Beta Sitosterol/Calcium Pantothenate/Dehydroepiandrosterone/Pentasterone/Pyridoxine 25 MG-700 MG-25 MG-6 MG Oral Tablet [DHEA PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA plus insulin infusion
Trial: 9059564
Drug: DHEA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA infusion alone
Trial: 22872648
Drug: PEG‐IFN first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN first (180 μg/week for 24 weeks followed by LdT 600 mg/day for 24 weeks)
Trial: 22872648
Drug: LdT first
RxNorm normalized name: LDT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LdT first (600 mg/day for 24 weeks followed by PEG‐IFN 180 μg/week for 24 weeks)
Trial: 21122961
Drug: 6‐times‐weekly in‐center
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐times‐weekly in‐center daily hemodialysis (1.5‐2.75 h/session)
Trial: 8509578
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray 100 micrograms twice daily
Trial: 7604951
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice daily
Trial: 17154747
Drug: Traditional Behavioral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Behavioral Couple Therapy (TBCT)
Trial: 11606830
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) - IV bolus dose of 15 mg/kg followed by a constant IV infusion of 10 mg/kg/hour until 12 hours after tourniquet deflation
Trial: 8016790
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (100 micrograms/puff, two puffs three times daily for eight weeks)
Trial: 18795264
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment
Trial: 24410736
Drug: Standard PD
RxNorm normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PD solutions
Trial: 22991015
Drug: Biocompatible PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible PD solutions
Trial: 22696191
Drug: Local TCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local TCA injections
Trial: 17585669
Drug: Jianying point-injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianying point-injection combined with massage
Trial: 19226897
Drug: Routine acupuncture
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupuncture therapy
Trial: 14998068
Drug: Naratriptan 2.5
RxNorm normalized name: naratriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naratriptan 2.5 mg
Trial: 3055454
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg 3 times daily for 5 d)
Trial: 24029535
Drug: Escitalopram 10-20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10-20 mg/day
Trial: 19816208
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of PRBC at a rate of 1 mL/kg/h (Group A)
Trial: 19816208
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of PRBC at a rate of 3 mL/kg/h (Group B)
Trial: 11911755
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin
Trial: 9462678
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy plus tamoxifen
Trial: 9462678
Drug: Control (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (early stage breast cancer not treated with systemic therapy)
Trial: 7993989
Drug: Oxcarbazepine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (600 mg) after overnight fasting
Trial: 7993989
Drug: Oxcarbazepine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (600 mg) after a fat‐ and protein‐rich breakfast
Trial: 31517876
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of standardized ashwagandha extract (Shoden) once daily
Trial: 21153029
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg
Trial: 21153029
Drug: Control (Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Aspirin 100 mg and Clopidogrel 75 mg)
Trial: 17719472
Drug: Torasemide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (10 to 20 mg/day)
Trial: 17719472
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 to 40 mg/day)
Trial: 11281231
Drug: Higher plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher plasma renin activity in white children (7.1 +/- 3.6 ng/mL/h)
Trial: 3737031
Drug: Aspirin-dipyridamole (990
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-dipyridamole (990 mg/225 mg/day)
Trial: 29682590
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose HBV vaccination (3 doses of 20μg) in healthy controls
Trial: 24695091
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day for 14 days
Trial: 24695091
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) 4000 AxaIU (0.4 ml)/day for 14 days
Trial: 18397549
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean modal dose 12.0 mg/day, average duration 241 days)
Trial: 18397549
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean modal dose 4.0 mg/day, average duration 86 days)
Trial: 12437647
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori therapy
Trial: 10692734
Drug: Omeprazole alone
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole alone followed by long-term famotidine 20 mg daily (Group B, n = 34)
Trial: 6712754
Drug: Oral pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pulse methotrexate therapy (2.5-5.0 mg every 12 hours in 3 consecutive doses per week)
Trial: 26421810
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg orally 2 hours before surgery and 24 hours after surgery)
Trial: 21195195
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg)